4,5-二氯-2-苄基-3(2H)-哒嗪 | 41933-33-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,5-二氯-2-苄基-3(2H)-哒嗪
• 中文别名: 2-苄基-4,5-二氯哒嗪-3-酮；2-苄基-4,5-二氯-2,3-二氢吡嗪-3-酮；2-苄基-4,5-二氯哒嗪-3(2H)-酮
• 英文名称: 2-benzyl-4,5-dichloro-3(2H)-pyridazinone
• 英文别名: 2-benzyl-4,5-dichloropyridazin-3(2H)-one；2-benzyl-4,5-dichloropyridazin-3-one
• CAS: 41933-33-9
• 化学式: C₁₁H₈Cl₂N₂O
• mdl: MFCD00067773
• 分子量: 255.103
• InChiKey: AJHBQZQCDCTOFD-UHFFFAOYSA-N

物化性质

• 熔点：
  86 °C(Solv: hexane (110-54-3))
• 沸点：
  338.0±52.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi,T
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36,R36/37/38,R25
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境中保存。

SDS

Name:	2-Benzyl-4 5-dichloro-2 3-dihydropyridazin-3-one 97% Material Safety Data Sheet
Synonym:	2-Benzyl-4,5-dichloropyridazine-3(2H)-on
CAS:	41933-33-9

Section 1 - Chemical Product MSDS Name:2-Benzyl-4 5-dichloro-2 3-dihydropyridazin-3-one 97% Material Safety Data Sheet
Synonym:2-Benzyl-4,5-dichloropyridazine-3(2H)-on

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
41933-33-9	2-Benzyl-4,5-dichloro-2,3-dihydropyrid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 41933-33-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 87 - 89 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H8Cl2N2O
Molecular Weight: 255

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 41933-33-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Benzyl-4,5-dichloro-2,3-dihydropyridazin-3-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 41933-33-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 41933-33-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 41933-33-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化合物EcDsbB-IN-9（即化合物9）是一种有效的大肠杆菌DsbB（EcDsbB）抑制剂，其IC50值为1.7μM，Ki值为46 nM。

反应信息

• 作为反应物：
  描述：

  4,5-二氯-2-苄基-3(2H)-哒嗪 在 氢碘酸 作用下， 反应 24.0h， 以88%的产率得到2-苄基-5-碘哒嗪-3-酮
  参考文献：
  名称：

  哒嗪衍生物。第39部分：5-碘哒嗪-3（2 H）-在钯催化的反应中的反应性

  摘要：

  在寻找新的抗血小板药中，据报道利用钯催化的交叉偶联反应制备2，5-二取代的哒嗪-3（2 H）-1的方便，有效的方法。在5-碘吡啶并嗪-3（2 H）-ones（3）与1-苯基-2-丙炔-1-醇的Sonogashira炔基化过程中，观察到了偶联后的碱基促进的异构化。在3的Heck烯基化过程中，副产物的量不同的邻苯二氮酮被分离出来。羟甲基片段作为5-取代哒嗪-3（2 H）-ones合成过程中的保护基的有效性已得到验证。

  DOI：

  10.1016/j.tet.2004.10.014
• 作为产物：
  描述：

  4,5-二氯-3-羟基哒嗪 生成 4,5-二氯-2-苄基-3(2H)-哒嗪
  参考文献：
  名称：

  MUTSUKADO, MOTOO;TANIKAWA, KEIZO;SHIKADA, KEN-ICHI;SAKODA, RYOZO

  摘要：

  DOI：
• 作为试剂：
  描述：

  4,5-二氯-3-羟基哒嗪 、 potassium carbonate 、 溴甲苯 、 3-哒嗪酮 在 水 、 resultant suspension 、 4,5-二氯-2-苄基-3(2H)-哒嗪 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.25h， 以to give the title compound, 2-benzyl-4,5-dichloropyridazin-3(2H)-one, (73.1 g, 95%) as pale yellow solid的产率得到4,5-二氯-2-苄基-3(2H)-哒嗪
  参考文献：
  名称：

  Azabicyclic heterocycles as cannabinoid receptor modulators

  摘要：

  本申请描述了按照公式I的化合物，包括至少一种按照公式I的化合物和可选的一种或多种其他治疗剂量的制药组合物，以及使用这些化合物的治疗方法，既可以单独使用，也可以与一种或多种其他治疗剂量联合使用。这些化合物具有一般公式I：包括所有的前药、药学可接受的盐和立体异构体，其中R1、R2、R3、R6、R7、m和n在此描述。

  公开号：

  US07378418B2

文献信息

• Design, synthesis, and bioactivities of novel pyridazinone derivatives containing <scp>2‐phenylthiazole</scp> or oxazole skeletons
  作者：Mingming Dang、Minhua Liu、Lu Huang、Xiaoming Ou、Chuyun Long、Xingping Liu、Yeguo Ren、Ping Zhang、Mingzhi Huang、Aiping Liu

  DOI：10.1002/jhet.4118

  日期：2020.11

  A series of novel pyridazinone derivatives were designed and synthesized by replacing 4‐(tert‐butyl)phenyl moiety of pyridaben with 2‐phenylthiazole or oxazole fragments via activity substructure connecting approach. The structures of all target compounds were characterized through NMR, MS, and elemental analysis. Bioassay results exhibit that most compounds showed potent bioactivities against Aphis

  通过活性亚结构连接方法，用2-苯基噻唑或恶唑片段取代了哒嗪的4-（叔丁基）苯基部分，设计并合成了一系列新型的哒嗪酮衍生物。所有目标化合物的结构均通过NMR，MS和元素分析表征。生物测定的结果表明，大多数化合物显示出对Fabs，Tetranychus urticae，Erysiphe graminis和/或Puccinia polysora的有效生物活性。在新合成的化合物中，2-（叔丁基）-4-氯5-（（（（2-苯基噻唑-4-基）甲基）硫基）哒嗪-3（2 H）-one（12b）对Fab表现出明显的杀虫活性。它的LC 50值（2.73 mg / L）比吡虫本（5.46 mg / L）好，尽管比吡虫啉（0.51 mg / L）低。除具有非凡的杀虫活性外，化合物12b在体内500 mg / L时对多聚磷也具有96.9％的杀真菌活性，显着优于吡达本（50.0％），但略低于戊唑醇（100％）。本文讨论
• Macrocyclic hepatitis C serine protease inhibitors
  申请人：Miao Zhenwei

  公开号：US20050153877A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I、II或III的化合物，或其药用可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过给主体投药包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2015103137A1

  公开（公告）日：2015-07-09

  Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.

  提供具有公式I的化合物或其立体异构体、互变异构体或药用可接受盐，这些化合物用于治疗疾病。公开了使用公式I的化合物或其立体异构体、互变异构体或药用可接受盐，用于体外、原位和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• [EN] IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS<br/>[FR] IMIDAZO[1,2-A]PYRIDINES ET IMIDAZO[1,2-B]PYRIDAZINES UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE MARK
  申请人：MERCK SHARP & DOHME

  公开号：WO2010083145A1

  公开（公告）日：2010-07-22

  The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.

  这项发明涵盖了选择性抑制微管亲和调节激酶（MARK）的咪唑并[1,2-a]吡啶和咪唑并[1,2-b]吡啶衍生物，因此对于治疗或预防阿尔茨海默病具有用处。药物组合物和使用方法也包括在内。
• 3(2H)Pyridazinone, process for its preparation and anti-allergic agent
  申请人：Nissan Chemical Industries Ltd.

  公开号：US04892947A1

  公开（公告）日：1990-01-09

  A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl, C.sub.3 -C.sub.6 alkenyl, C.sub.5 or C.sub.6 cycloalkyl, benzyl, phenyl, --(CH.sub.2).sub.m CO.sub.2 R.sub.3 (wherein R.sub.3 is hydrogen or C.sub.1 -C.sub.5 alkyl, and m is an integer of from 1 to 4), --(CH.sub.2).sub.n A (wherein A is --OH or --N(R.sub.4).sub.2 wherein R.sub.4 is C.sub.1 -C.sub.3 alkyl, and n is an integer of from 2 to 6) or --CH.sub.2 CF.sub.3 ; R.sub.2 is chlorine or bromine; each of Y.sub.1 and Y.sub.2 which may be the same or different, is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --OR.sub.5 (wherein R.sub.5 is hydrogen, C.sub.1 -C.sub.8 alkyl or ##STR2## wherein q is an integer of from 1 to 4), --CO.sub.2 R.sub.6 (wherein R.sub.6 is hydrogen or C.sub.1 -C.sub.5 alkyl), --N(R.sub.7).sub.2 (wherein R.sub.7 is C.sub.1 -C.sub.4 alkyl) or --SR.sub.8 (wherein R.sub.8 is C.sub.1 -C.sub.4 alkyl); and Y.sub.3 is C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --OR.sub.5 (wherein R.sub.5 is as defined above), --CO.sub.2 R.sub.6 (wherein R.sub.6 is as defined above), --N(R.sub.7).sub.2 (wherein R.sub.7 is as defined above) or --SR.sub.8 (wherein R.sub.8 is as defined above), or a pharmaceutically acceptable salt thereof.

  该公式中的3-(2H)吡啶并嗪酮如下：其中R₁是氢、甲基、C₃-C₆烯基、C₅或C₆环烷基、苄基、苯基、--(CH₂)ₘCO₂R₃（其中R₃是氢或C₁-C₅烷基，m为1至4之间的整数），--(CH₂)ₙA（其中A为--OH或--N(R₄)₂，其中R₄为C₁-C₃烷基，n为2至6之间的整数）或--CH₂CF₃；R₂是氯或溴；Y₁和Y₂分别为氢、C₁-C₅烷基、C₂-C₈烯基、卤素、--OR₅（其中R₅为氢、C₁-C₈烷基或所述的##STR2##其中q为1至4之间的整数），--CO₂R₆（其中R₆为氢或C₁-C₅烷基），--N(R₇)₂（其中R₇为C₁-C₄烷基）或--SR₈（其中R₈为C₁-C₄烷基）；Y₃为C₁-C₅烷基、C₂-C₈烯基、卤素、--OR₅（其中R₅如上所定义），--CO₂R₆（其中R₆如上所定义），--N(R₇)₂（其中R₇如上所定义）或--SR₈（其中R₈如上所定义），或其药学上可接受的盐。